Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
about
Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.Targeting malignant B cells with an immunotoxin against ROR1Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549)Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigensGlycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Engineering Natural Killer Cells for Cancer Immunotherapy.A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.Natural killer cells modulation in hematological malignancies.Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
P2860
Q28829762-E22173BD-40EF-45C6-B64D-3F3CB387B2EEQ34613920-5452B3E8-D428-4FF9-AC71-891FB7B045EAQ35969887-FDFF4D4F-DFED-4DCA-9B43-422532EE6442Q36311218-519D6699-0E59-4FB7-8969-478A09562A0AQ36377047-F17DADC7-F3CE-4433-8F8F-0519C58CC9E7Q37364355-7CC7ABE0-618C-4490-B248-B59D2815F0FFQ37434670-2BAF37D3-BEFB-465A-884F-CAFF5BA6DA9DQ37810901-C43C2AD8-9C9E-4411-8250-3429314B3CECQ38542034-23D3859F-9428-4EEE-9968-7618C7E3E4F8Q39408704-B7776C8F-D359-4222-B260-9E8F5D2BF153Q41791356-7DC9AE3B-DA6E-4E47-B851-12BCF64E60EFQ41982546-0596D71D-4BAB-4957-B669-862D6ED62546Q57583335-6173A649-1A43-4F17-AFCB-17C851A3FA4E
P2860
Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@ast
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@en
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@nl
type
label
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@ast
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@en
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@nl
prefLabel
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@ast
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@en
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P921
P1433
P1476
Variable contribution of monoc ...... chronic lymphocytic leukemia.
@en
P2093
Andreas Klein
Arthur P Rabinowitz
Hans Klingemann
James Weitzman
Laurent Boissel
Monica Betancur
P2860
P304
P356
10.1080/10428190903026500
P577
2009-08-01T00:00:00Z